Role
The advisory group consists of clinical professionals from the Haemopoietic Progenitor Cell (HPC) sector. They will make recommendations to the Jurisdictional Haemopoietic Progenitor Cell Committee (JHPCC) on future HPC sector reform proposed within the National Haemopoietic Progenitor Cell Framework.
For more information on the roles and responsibilities of the advisory group, see the HPC Sector Clinical Advisory Group Governance resource and Terms of Reference.
Haemopoietic Progenitor Cell Sector Clinical Advisory Group Governance
Terms of Reference – Haemopoietic Progenitor Cell Sector Clinical Advisory Group
Members
We appoint members for their expertise in clinical haematology, tissue typing, laboratory accreditation and regulatory frameworks.
Member | Role / Expertise | Position |
---|---|---|
Dr Neil Everest, (Chair) | Clinical & public health; medicines & biologicals regulation; health technology assessment & reimbursement | Senior Medical Adviser, Technology Assessment and Access Division, Department of Health and Aged Care |
Prof Robert Carroll | Clinical Nephrologist & Tissue Typing Specialist | Senior Nephrologist, South Australia Health, SA National Clinical Lead, Transplant Immunogenetics Service, Lifeblood Australian Redcross Blood Service. |
Ms Natalie Clark Reynolds | Consumer representative | Consumer representative |
Ms Sophy Suy | NATA representative | Lead Accreditation Specialist, National Association of Testing Authorities (NATA) Australia |
A/Prof Anna Johnston | Clinical Haematologist and Transplant Physician | Head of Clinical Haematology and Bone Marrow Transplant, Royal Hobart Hospital, TAS Director, State-wide Bone Marrow Transplant Service, TAS |
Prof Ian Kerridge | Clinical Haematologist, Transplant Physician and Bioethicist | Staff Haematologist and Bone Marrow Transplant Physician, Royal North Shore Hospital, NSW Prof of Bioethics and Medicine, University of Sydney, NSW |
Ms Shraddha Swami | TGA representative | Director, Devices In Vitro Diagnostics Section, Medical Devices Authorisation Branch, Therapeutic Goods Administration, Department of Health and Aged Care |
Dr Richard Mitchell | Clinical Haematologist and Oncologist, Paediatric Transplant Physician | Director, Kids Cancer Centre, Sydney Children’s Hospital, NSW |
Dr Shanti Ramachandran | Consultant Paediatric and Adolescent Oncologist, Transplantation and Cellular therapy | BMT Physician, Consultant Paediatric and Adolescent Haematology-Oncology, Child and Adolescent Health Services, Perth Children's Hospital |
Dr Beverley Rowbotham | Clinical Haematologist and Accreditation Specialist | Consultant Haematologist, Sullivan Nicolaides Pathology, QLD Chair, National Pathology Accreditation Advisory Council, Department of Health and Aged Care |
Prof Erica Wood | Clinical Haematologist | Consultant Haematologist, Monash Health, VIC Prof and Head, Transfusion Research Unit, Monash University, VIC |
Prof David Yeung | Clinical Haematologist and Transplant Physician | Head of Haematology, Royal Adelaide and The Queen Elizabeth Hospitals, SA Consultant Haematologist, Royal Adelaide Hospital and South Australia Pathology, SA |
A/Prof Glen Kennedy | Clinical Haematologist and Transplant Physician | Executive Director, Cancer Care Services, RBWH Acting Executive Director, Clinical Services, MNHHS |
If the Advisory Group requires other expertise, we will invite more clinical and non-clinical experts to participate.
Meetings
The HPC Sector Clinical Advisory Group will meet at least four times per year.
Reports
In May 2023, the HPC Sector Clinical Advisory Group provided its Recommendations on Adult Haemopoietic Progenitor Cell Donor Recruitment Reform to the JHPCC.
This advice:
- included point-in-time data and references to service providers that currently have a role in HPC donor recruitment
- outlined what those roles might look like if they were to be maintained.
These recommendations are not intended to direct the roles of service providers in the future, or prejudice future contractual arrangements or procurement activities, which are decisions for all governments based on this advice and other considerations.
These recommendations are being considered by all governments and, where supported, will be prioritised according to need and available resources.